Promising liposarcoma drug trial halted early
NCT ID NCT05496569
First seen Nov 21, 2025 · Last updated Jun 17, 2026 · Updated 20 times
Summary
This study tested a new drug called TQB3616 for people with a rare type of fat tissue cancer called dedifferentiated liposarcoma that could not be removed by surgery. The goal was to see if the drug could slow down cancer growth compared to a placebo. The trial was stopped early and enrolled only 26 participants instead of the planned 118.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEDIFFERENTIATED LIPOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
-
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, 200032, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.